How effective is Methotrexate Lpf for Sarcoidosis? (a real world drug study)
Summary:
Overall ratings: 3/5 Long term ratings: 0/5
This is a phase IV clinical study of how effective Methotrexate lpf (methotrexate sodium) is for Sarcoidosis and for what kind of people. The study is created by eHealthMe from 3 Methotrexate lpf users and is updated continuously.
What is Methotrexate lpf?
Methotrexate lpf has active ingredients of methotrexate sodium. It is often used in rheumatoid arthritis. eHealthMe is studying from 636 Methotrexate lpf users. Check the latest studies of Methotrexate lpf.
What is Sarcoidosis?
Sarcoidosis (an inflammatory disease that affects multiple organs in the body, but mostly the lungs and lymph glands) is found to be associated with 547 drugs and 611 conditions by eHealthMe. Check the latest studies of Sarcoidosis.
eHealthMe: drug outcomes in the real world
eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.
3 people are studied for taking Methotrexate lpf in Sarcoidosis
Overall effectiveness (number of people):
Long term (1+ years) effectiveness (number of people):
Methotrexate lpf effectiveness for Sarcoidosis (number of people):
Overall:
- not at all: 0
- somewhat: 1
- moderate: 1
- high: 1
- very high: 0
Long Term:
- not at all: 0
- somewhat: 0
- moderate: 0
- high: 0
- very high: 0
Gender of people who take Methotrexate lpf for Sarcoidosis *:
- female: 100 %
- male: 0.0 %
Age of people who take Methotrexate lpf for Sarcoidosis *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 0.0 %
- 40-49: 0.0 %
- 50-59: 66.67 %
- 60+: 33.33 %
Who find Methotrexate Lpf more effective for Sarcoidosis?
Gender of people who take Methotrexate lpf for Sarcoidosis *:
- female: 100 %
- male: 0.0 %
Age of people who take Methotrexate lpf for Sarcoidosis *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 0.0 %
- 40-49: 0.0 %
- 50-59: 100 %
- 60+: 0.0 %
* Approximation only. Some reports may have incomplete information.
Do you take Methotrexate lpf?
- You can start a phase IV clinical trial to monitor Methotrexate lpf safety and effectiveness.How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Related publications that referenced our studies:
- ?UPANI? KRMEK DU, BRAJKOVI? I, BEKI? D, KRNI? A, JURKOVI? P, PAVLOVI? T, "CALCIFIED DEEP VEIN THROMBOSIS IN A PATIENT WITH RECURRENT DEEP VEIN THROMBOSIS AND SARCOIDOSIS", Acta Medica Croatica, 2014 Mar .
- Khedr YA, Khedr AH, "Sarcoidosis patient: an unexpected reaction to carbonic anhydrase enzyme inhibitor", BMJ case reports, 2013 Jul .
- Kang SM, Baek JY, Hwangbo B, Kim HY, Lee GK, Lee HS, "A case of capecitabine-induced sarcoidosis", Tuberculosis and respiratory diseases, 2012 Mar .
- ?UPANI? KRMEK DU, BRAJKOVI? I, BEKI? D, KRNI? A, JURKOVI? P, PAVLOVI? T, "CALCIFIED DEEP VEIN THROMBOSIS IN A PATIENT WITH RECURRENT DEEP VEIN THROMBOSIS AND SARCOIDOSIS", Acta Medica Croatica, 2014 Mar .
- Khedr YA, Khedr AH, "Sarcoidosis patient: an unexpected reaction to carbonic anhydrase enzyme inhibitor", BMJ case reports, 2013 Jul .
- Kang SM, Baek JY, Hwangbo B, Kim HY, Lee GK, Lee HS, "A case of capecitabine-induced sarcoidosis", Tuberculosis and respiratory diseases, 2012 Mar .
Related studies
Alternative drugs to, pros and cons of:
- Methotrexate lpf (636 reports)
Treatments, associated drugs and conditions:
- Sarcoidosis (11,686 reports)
How the study uses the data?
The study is based on methotrexate sodium (the active ingredients of Methotrexate lpf) and Methotrexate lpf (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study neither.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Losartan cause Skin Sensitisation? - 5 seconds ago
- Diabetes and Calcium Deficiency - 7 seconds ago
- Could Keppra cause Hypoxic-Ischaemic Encephalopathy? - 14 seconds ago
- Could Vancomycin Hydrochloride cause Myelodysplastic Syndrome? - 24 seconds ago
- Musculoskeletal Chest Pain and drugs of ingredients of mupirocin - 25 seconds ago
- Losartan and Nosebleed for Women aged 40-49 - 44 seconds ago
- Losartan and Nose Bleed for Women aged 40-49 - 44 seconds ago
- Losartan and Nose Bleeds for Women aged 40-49 - 44 seconds ago
- Losartan and Nosebleeds for Women aged 40-49 - 45 seconds ago
- Losartan and Epistaxis for Women aged 40-49 - 45 seconds ago